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Abstract: Recent guidelines for the management of hypertension recommend target blood 
pressures 140/90 mmHg in hypertensive patients, or 130/80 mmHg in subjects with diabetes, 
chronic kidney disease, or coronary artery disease. Despite the availability and efficacy of antihy-
pertensive drugs, most hypertensive patients do not reach the recommended treatment targets with 
monotherapy, making combination therapy necessary to achieve the therapeutic goal. Combination 
therapy with 2 or more agents is the most effective method for achieving strict blood pressure 
goals. Fixed-dose combination simplifies treatment, reduces costs, and improves adherence. There 
are many drug choices for combination therapy, but few data are available about the efficacy and 
safety of some specific combinations. Combination therapy of calcium antagonists and inhibitors 
of the renin-angiotensin-aldosterone system (RAAS) are efficacious and safe, and have been 
considered rational by both the JNC 7 and the 2007 European Society of Hypertension – European 
Society of Cardiology guidelines for the management of arterial hypertension. The aim of this 
review is to discuss some relevant issues about the use of combinations with calcium channel 
blockers and RAAS inhibitors in the treatment of hypertension.
Keywords: hypertension, calcium channel blockers, renin-angiotensin-aldosterone system 
inhibitors, fixed-dose combination, adherence
Introduction
Hypertension is still a major public health issue, affecting millions of patients world-
wide. Although control rates have improved during the past years, the actual rate is still 
unacceptably low, and control rates in more vulnerable populations, such as persons 
with diabetes mellitus, are even lower. Because hypertension is a major risk factor for 
cardiac and cerebrovascular events, patients with uncontrolled or poorly controlled 
blood pressure (BP) are at high risk for serious morbidity and mortality.1,2
Hypertension has a prevalence of 30.1% in Mexico (and only 19% of these cases 
are controlled), and its prevalence continues to increase; 49% of hypertensive patients 
in Mexico are obese (body mass index [BMI]  30 kg/m2).3
Optimal BP control could prevent a high percentage of coronary heart disease 
events, and early BP control significantly reduces the risk of stroke and cardiovascular 
events.1
Despite the availability and efficacy of antihypertensive drugs, almost 70% 
of hypertensive patients do not reach the recommended treatment target of 140/90 mmHg 
with monotherapy, and only a small proportion of high risk patients reaches the goal 
of 130/80 mmHg (in patients with diabetes, chronic kidney disease, or coronary artery 
disease), making combination therapy necessary to achieve these targets with minimal Integrated Blood Pressure Control 2009:2 56
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adverse effects. The extra BP reduction from combining drugs 
from two different classes is approximately 2 to 5 times greater 
than doubling the dose of one drug.4,5 In both cases, combi-
nation therapy results in more effective and more prompt BP 
lowering, at lower doses. Compared with free combinations 
(drugs in different pills), fixed-dose regimens (both drugs in 
the same pill) have the advantages of greater convenience and 
potentially reduced costs, both of which may translate into 
improved adherence and superior BP reductions.6 Indeed 
both the Seventh Report of the Joint National Committee 
on Prevention, Detection, Evaluation and Treatment of High 
Blood Pressure (JNC7),1 and the 2007 European Society of 
Hypertension and the European Society of Cardiology guide-
lines (ESHCG) for the management of arterial hypertension,7 
recommended considering using 2 or 3 drugs or combination 
therapy for patients in whom the probability of achieving BP 
control with monotherapy is low, such as patients with systolic 
BP higher than 20 mmHg or diastolic BP higher than 10 mmHg 
from the therapeutic goal. Table 1 describes the advantages of 
combination therapy.
Clinicians have many drug choices for combination 
therapy, but few data are available for the efficacy and safety 
of some specific combinations; this is especially true for fixed-
dose combinations. Most fixed-dose combinations include 
a diuretic, and have been shown to provide BP reductions 
greater than those seen with monotherapy.5 Combination 
therapy of calcium antagonists plus inhibitors of the renin-
angiotensin-aldosterone system (RAAS) are efficacious and 
safe, and represent a new addition to the available antihyper-
tensive treatment options.6,8 This combination therapy acts on 
several pathways that increase BP in hypertensive patients, 
ie, blocking the renin-angiotensin system, relaxing vascular 
smooth muscle, with a reduction of peripheral resistance, 
and both inhibitors of the RAAS and calcium antagonists can 
counteract the hypertensive effect of endothelin-1.9 The 2 drug 
families improve endothelial function and insulin resistance.6,9 
These combinations have been considered rational by both 
the JNC 71 and the ESHCG.7 Table 2 shows the fixed-dose 
combinations of a RAAS inhibitor with the currently available 
calcium channel blockers (CCB).
In this review we analyze the combination therapy of 
CCB with inhibitors of the RAAS: the data on its efficacy, 
safety and advantages beyond its antihypertensive effect, 
with emphasis on fixed-dose combinations.
Therapeutic efficacy
A combination therapy of calcium antagonists plus inhibi-
tors of the RAAS provides higher antihypertensive efficacy 
and is usually well tolerated. Several trials have assessed the 
potential of such combinations.9
The combination of these classes of drugs may be superior 
to other combinations for target organ protection, a meta-
analysis having shown that angiotensin-converting enzyme 
(ACE) inhibitors appear superior to CCB for prevention of 
coronary heart disease, whereas CCB appear superior to ACE 
inhibitors for prevention of stroke. Therefore, the combina-
tion of these agents could offer the rationale for a broad-
spectrum cardiovascular and cerebrovascular prevention.10
In an Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial (ALLHAT) subanalysis, the ACE 
inhibitor lisinopril showed a superior effect over the CCB 
for heart failure prevention, but the CCB amlodipine was 
superior to the ACE inhibitor for stroke prevention,11 findings 
that agree with those of the previous meta-analysis.10
ACe inhibitors/calcium antagonists 
combinations
The hemodynamic profile of this combination is peripheral 
vasodilatation without sodium and fluid retention, with 
reduction of peripheral resistance and improvement of left 
ventricular function.9
In the Avoiding Cardiovascular Events Through Combina-
tion Therapy in Patients Living With Systolic Hypertension 
(ACCOMPLISH) trial,12 the first trial designed to compare 
Table 1 Advantages of combining antihypertensive agents
Combination of 2 agents at low doses gives greater blood pressure 
reductions than higher dose of 1 drug
Fewer adverse effects
Blockade of several pathways that increase blood pressure
Increased protection of target organs
Prompt blood pressure control
effects beyond their antihypertensive actions
Table 2 Currently available fixed-dose combinations
ACE inhibitor and CCB References
Ramipiril/felodipine
Benazepril/amlodipine 11,25,35
Delapril/manidipine 34
Trandolapril/verapamil 13,14,26,28,30
ARB and CCB
valsartan/amlodipine 18
Abbreviations: ACe, angiotensin converting enzyme;   ARB, angiotensin receptor blocker; 
CCB, calcium channel blocker.Integrated Blood Pressure Control 2009:2 57
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the fixed-dose combination of an ACE inhibitor plus a CCB 
with another combination, the antihypertensive efficacy of the 
fixed-dose combination benazepril/amlodipine was compared 
with that of the combination benazepril/hydrochlorothiazide 
in more than 11,400 high risk patients aged 55 years. After 
a follow-up of 36 months (the study was finished early), both 
treatments reached the BP goal of less than 140/90 mmHg 
in more than 75% of patients. However, hard cardiovascular 
(CV) endpoints (CV death, stroke, and myocardial infarction) 
were reduced by 20% (P = 0.007) in the benazepril/amlodipine 
group, and a cardiovascular morbidity/mortality reduction of 
20% (P = 0.0002) in that group was noted, too.
In  the Anglo  Scandinavian  Cardiac  Outcomes 
Trial–Blood Pressure Lowering Arm (ASCOT-BPLA), 
the amlodipine-based therapy (with perindopril added 
if necessary, although not in fixed-dose combination) 
was compared with an atenolol-based therapy (with 
bendroflumethiazide added if necessary) in 19,257 
high risk hypertensive patients.13 After a median 5.5 years of 
follow-up, amlodipine/perindopril was more effective than 
atenolol/thiazide in decreasing fatal and nonfatal stroke, 
total cardiovascular events, and all-cause mortality (all 
secondary endpoints). The amlodipine/perindopril group 
also had a significantly lower incidence of new-onset dia-
betes compared with the atenolol/thiazide group.
The INternational VErapamil SR/trandolapril Study 
(INVEST), a verapamil SR-based treatment strategy, with 
trandolapril added, was as effective as an atenolol-based 
treatment strategy (which also included the addition of 
trandolapril) in reducing the risk of the primary outcomes 
of death (all-cause), nonfatal myocardial infarction, or 
nonfatal stroke in patients with hypertension and coro-
nary artery disease.14 In the INVEST trial, the verapamil/
trandolapril group also had a significantly lower incidence of 
new-onset diabetes compared with the atenolol/trandolapril 
group.
We have found that the fixed-dose combination of 
trandolapril/verapamil is an effective and safe option for the 
management of stage 2 hypertension in Mexican patients 
uncontrolled by monotherapy,15 with a low incidence of 
adverse effects (1 case of constipation).
Based on the papers reviewed above, the combination 
of an ACE inhibitor with a CCB (dihydropiridine or 
nondihydropiridine) is effective and safe for the management 
of hypertensive patients, including subjects uncontrolled 
by monotherapy, and obese and high risk patients. This 
combination has been shown to reduce cardiovascular 
and cerebrovascular endpoints and is well tolerated. 
The metabolic advantages of the combination will be 
commented on later.
It is important to note that because ACE inhibitors 
produce arterial and venous vasodilation, they reduce the 
incidence of CCB-induced ankle edema, and counteract the 
RAAS and sympathetic stimulation promoted by CCB;16 
therefore the combination also has a lower incidence of 
adverse effects than monotherapy.
Combination of a CCB and an angiotensin 
receptor blocker
The hemodynamic profile of this combination is also 
peripheral vasodilatation without sodium and fluid retention, 
with reduction of peripheral resistance and improvement of 
left ventricular function.4
Although this combination is less studied than com-
binations that include an ACE inhibitor, several recently 
published short-term studies assessing the efficacy and 
tolerability of amlodipine plus various angiotensin receptor 
blockers (ARB) in patients with mild to moderate hyperten-
sion show promising results, but no head to head studies of 
these combinations have been published.17
In a randomized, double-blind study, the safety and 
efficacy of the combination of amlodipine/valsartan in 
patients with stage 2 hypertension was compared with 
the combination of lisinopril/hydrochlorothiazide;18 both 
regimens reduced BP significantly after a 6 weeks of 
follow-up, and there were no differences between them.
In the Exforge in Failure after Single Therapy (EX-FAST) 
study, 894 patients uncontrolled with monotherapy were 
switched to amlodipine/valsartan, and followed for 
16 weeks, when the therapeutic goals (140/90 mmHg 
or 130/80 mmHg for diabetes patients) were reached by 
74.8% of patients.19
In the Combination of Olmesartan medoximil and Amlo-
dipine besylate in Controlling High blood pressure (COACH) 
trial, the combination of olmesartan/amlodipine was superior 
to higher doses of each drug in monotherapy for BP reduc-
tions in 1940 patients with mild to severe hypertension after 
8 weeks of treatment;20 the combination was well tolerated.
In a recent study that included 1461 patients followed 
for 8 weeks, the combination of telmisartan/amlodipine 
significantly decreased BP in patients with hypertension 
stage 1 or 2.21
ARB also reduce the incidence of CCB-induced ankle 
edema, perhaps in the same way as do ACE inhibitors;17 
therefore this combination has fewer side effects than the 
monotherapy.Integrated Blood Pressure Control 2009:2 58
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Although less studied than combinations of an ACE 
inhibitor and a calcium antagonist, and without results 
on hard cardiovascular endpoints and from long-term 
randomized trials, the combination of an ARB and a CCB 
seems to be effective and safe for the management of 
uncontrolled hypertensive patients.
Aliskiren plus CCB
Two recent studies have evaluated the effect of the direct 
renin inhibitor aliskiren/amlodipine (not in fixed-dose). The 
first assessed the long-term efficacy and safety of aliskiren 
in comparison with the diuretic hydrochlorothiazide in 
1124 patients with essential hypertension; in both groups 
amlodipine was added on week 12, and after a follow-up of 
52 weeks, aliskiren/amlodipine treatment provided signifi-
cantly greater BP reductions than the respective hydrochlo-
rothiazide (with amlodipine added) regimen; aliskiren-based 
therapy was well tolerated.22
In the second study with 556 patients with hypertension 
stage 1 or 2,23 the combination of aliskiren/amlodipine effec-
tively reduced BP after a 52 weeks’ follow-up, particularly 
in patients with hypertension stage 2, with a low incidence 
of ankle edema.
As the available information for the combination of 
aliskiren and CCB is limited, especially in a fixed-dose 
formulation, more studies with this combination are 
needed.
Effects beyond their 
antihypertensive actions
Anti-inflammatory effects
Both RAAS inhibitors24 and CCB25 have shown an 
anti-inflammatory effect, mainly because they decrease some 
mediators of inflammation.
Siragy found that the combination of benazepril/
amlodipine produced a greater reduction in tumor necrosis 
factor-α and interleukin-6 than either drug alone in ischemic 
rats, providing more evidence for the anti-inflammatory 
synergism between an ACE inhibitor with a CCB.26
We have shown that although trandolapril and its 
fixed-dose combination with verapamil reduce the levels of 
circulating soluble adhesion molecules, trandolapril with 
verapamil (TV) produces a greater reduction in VCAM-1 
levels than trandolapril alone in type 2 diabetes patients with 
hypertension.27
As these mediators participate in the development of 
target organ damage in diabetes and hypertension,28 it is 
possible that the protection unrelated to the antihypertensive 
effect given by these combinations may be mediated, at least 
in part, by this anti-inflammatory effect. This requires further 
investigation.
Metabolic effects
As noted above, in both the ASCOT-BPLA13 and the 
INVEST14 trials, the combination of a RAAS inhibitor with 
a CCB shows a significantly lower incidence of new-onset 
diabetes; however, in these trials they were compared with 
a combination that included a β blocker (INVEST), or the 
combination of a β blocker with a thiazide (ASCOTBPLA). 
Several studies have demonstrated increased risk of new-
onset diabetes in patients treated with both thiazide diuretics 
or β blockers.7
In the Study of Trandolapril-Verapamil SR And Insulin 
Resistance (STAR), 240 patients with impaired glucose 
tolerance, normal kidney function, and hypertension 
received the fixed-dose combination of TV or losartan/
hydrochlorothiazide (LH), with a follow-up of 1 year. At the 
end of the study, TV reduced significantly the risk of new-
onset diabetes compared with LH.29
In the STAR Long-Term Extension Trial (STAR-LET), 
patients previously randomized to LH in the STAR trial were 
switched to TV therapy in a 6-month open-label extension.30 
At the end of the study, there was a reversal on half of the 
cases of new-onset diabetes that occurred during the original 
trial in the LH group, once they were switched to TV .
The findings of these 2 trials were attributed to the 
presence of hydrochlorothiazide in the LH group, and the 
persistence of its diabetogenic effect in spite of the inhibition 
of RAAS with losartan. However, we found that normotensive 
diabetes patients treated with the fixed-dose TV combination 
(for nephroprotection) reached a better fasting glycemic 
control than normotensive diabetes patients treated with 
monotherapy with trandolapril after 6 months of treatment. 
In that trial no patient received diuretics,31 leading us to 
hypothesize that the fixed-dose TV combination may have 
a role in glycemic control unrelated to its antihypertensive 
effect.
We found that fixed-dose TV produces a greater reduction 
in resistin levels than trandolapril alone.32 Resistin is an adi-
pocitokyne that antagonizes the effect of insulin on glucose 
metabolism and favors the development of diabetes.33 This 
effect may explain, at least in part, the favorable metabolic 
actions of TV , but this issue requires further investigation.
It is important to note that Roca-Cusachs et al34 found 
that after 12 weeks of treatment of 304 hypertensive diabetes 
patients with the fixed-dose combination manidipine/delapril Integrated Blood Pressure Control 2009:2 59
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versus the combination losartan/hydrochlorothiazide, 
more patients in the losartan/hydrochlorothiazide group 
suffered a non-significant increase in HbA1c levels (7.9% 
in the manidipine/delapril group vs 17.4% in the losartan/
hydrochlorothiazide group).
ESHCG further recommend use of an ACE inhibitor or 
an ARB in patients with metabolic syndrome or at high risk 
for the development of diabetes,7 and when a second agent 
is needed, a CCB is suggested as an appropriate option 
(dihydropiridine or non-dihydropiridine).
In type 2 diabetes patients, RAAS inhibitor/CCB 
combination therapy may offer benefits to patients beyond 
BP lowering.
In the Fosinopril versus Amlodipine Cardiovascular 
Events randomized Trial (FACET), an open label, prospec-
tive study,35 380 hypertensive type 2 diabetes patients were 
randomized to fosinopril or amlodipine, and if BP was not 
controlled, the other study drug was added. After 3.5 years 
of treatment, 28.4% of patients received both agents, and 
those patients on combination therapy had a lower risk of 
acute myocardial infarction, hospitalized angina, and stroke 
(all secondary endpoints of the study), compared with 
monotherapy.
As in FACET, in ACCOMPLISH12 and ASCOTBPLA13 
combination therapy of a CCB with a RAAS inhibitor 
reduced the incidence of cardiovascular complications and 
stroke compared with other therapies (monotherapy or com-
bined therapy). The benefits of the combination of a RAAS 
inhibitor plus a CCB that lead to cardiovascular prevention 
are clear, but the reasons for such outcomes are not.
The pathways that explain the CV and cerebrovascular 
outcomes with the combination of a RAAS inhibitor with 
a CCB may be related to the organ protective properties 
of both classes of drugs plus those of the combination, ie, 
anti-inflammatory,26,27 antioxidative, and antiatherosclerotic 
actions, and central aortic pressure reduction.8 In a small 
study of patients with hypertension and type 2 diabetes, 
fixed-dose combination therapy with amlodipine/benazepril 
improved large-artery compliance to a greater extent than did 
monotherapy with enalapril, despite attainment of similar 
BP levels. Decreased arterial compliance may frequently 
precede cardiovascular events and serve as a sensitive marker 
for at-risk patients.36
Kidney protection
Several studies in diabetes patients show that RAAS 
inhibitors37 and nondihydropiridine CCB38 decrease protein-
uria and the rate of creatinine clearance decline; therefore a 
combination of a RAAS inhibitor with a CCB should have a 
higher renoprotective effect than monotherapy.
In a randomized, open label study in 44 hypertensive 
type 2 diabetes patients with nephropathy, the trandolapril/
verapamil combination produced a greater reduction in pro-
teinuria over either agent alone at 1 year. When changes in 
BP were correlated, the reduction in proteinuria could not be 
differentiated from the degree of BP reduction.39
We found that the fixed-dose combination of TV 
effectively reduced albuminuria in 30 hypertensive type 2 
diabetes patients whose hypertension was unresponsive to 
at least 6 months of antihypertensive treatment with an 
ACE inhibitor;40 however, because in this study BP had an 
important reduction after the study duration of 6 months, 
we could not ascertain whether the reduction in albuminuria 
was secondary to the BP reduction or to a pleiotropic effect 
of the combination.
Our group also found that the same fixed-dose combination 
of TV reduced albuminuria to a greater extent than did mono-
therapy with trandolapril (and did not alter the glomerular fil-
tration rate, which was significantly reduced by trandolapril), 
after 6 months of treatment in 60 type 2 diabetes normotensive 
patients with albuminura 300 mg/24 hours, and who had not 
received prior treatment with antihypertensive drugs.32 We did 
not record a significant change in BP with the treatment.
In the Bergamo Nephrologic Diabetes Complications 
Trial (BENEDICT), 1204 hypertensive patients with type 2 
diabetes and normoalbuminuria were randomly assigned 
to receive trandolapril, verapamil, the combination of both 
drugs or placebo during 3.6 years. The combination TV 
significantly delayed the onset of microalbuminuria (by a 
factor of 2.6), whereas trandolapril monotherapy delayed the 
onset of microalbuminuria by a factor of 2.1 and verapamil 
did not delay the onset of microalbuminuria.41
In a small study in 15 type 1 diabetes normotensive 
patients with incipient diabetic nephropathy,42 the combina-
tion TV significantly decreased urinary albumin excretion 
within 1 year of treatment (a significant decrease of fasting 
plasma glucose was also noted).
We found that the fixed-dose combination TV produced 
a greater reduction in albuminuria than trandolapril alone in 
40 hypertensive type 2 diabetes patients after 3 months of 
treatment,27 and that reduction was unrelated to the decrease 
in BP.
When the effects of combinations that include a 
dihydropiridine CCB have been explored for the prevention 
or management of diabetic nephropathy, results have been 
controversial.Integrated Blood Pressure Control 2009:2 60
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In the GaUging Albuminuria Reduction with lotrel 
in Diabetic patients with hypertension (GUARD) study, 
after 1 year of treatment,43 the combination benazepril/
hydrochlorothiazide resulted in a greater reduction of 
albuminuria compared with the combination benazepril/
amlodipine in 332 hypertensive type 2 diabetes patients.
The combination fosinopril/amlodipine provided a 
greater antialbuminuric effect than both monotherapies in 
453 hypertensive type 2 diabetes patients after 48 months of 
treatment; however, the combination therapy had a greater 
antihypertensive effect, which could explain the results. 
In this study,44 cardiovascular outcomes were lower in the 
combination group.
Two studies have compared the effect of combinations 
of dihydropiridine versus a non-dihydropiridine CCB plus 
a RAAS inhibitor in albuminuria.
In a randomized trial, 45,304 type 2 diabetes hypertensive 
patients received the combination TV or benazepril/amlodipine. 
After 36 weeks’ follow-up, both treatments reduced albumin-
uria, but neither combination was superior to the other.
In the Verapamil versus Amlodipine in Nondiabetic 
Nephropathies Treated with Trandolapril (VVANNTT) 
study,46 proteinuria was reduced significantly after 1 month 
of monotherapy with trandolapril in non-diabetes patients. 
At the end of this period, patients were randomized to receive, 
in a double-blind fashion, either amlodipine or verapamil. 
After 8 months of follow-up, there was a slight but non-
significant reduction in proteinuria in both groups.
A small study in hypertensive type 2 diabetes patients 
with nephropathy compared the combination candesartan/
amlodipine with temocapril/candesartan. Both regimens 
reduced BP to the same extent,47 and the temocapril/
candesartan combination showed a greater antiproteinuric 
effect. However, this combination was associated with an 
increase in serum potassium and with worsening of renal 
anemia. It is important to bear all this in mind in relation 
to the renal outcomes of the Ongoing Telmisartan Alone 
or in combination with Ramipril Global Endpoint Trial 
(ONTARGET). In this trial, although combination therapy 
of an ACE inhibitor with an ARB reduced proteinuria to a 
greater extent than monotherapy,48 it also worsened major 
renal outcomes. This result raises the possibility that a 
combination of a RAAS inhibitor with a CCB may be safer 
than the combination of an ACE inhibitor with an ARB.
Based on the information available, the combination 
of a RAAS inhibitor plus a CCB (dihydropiridine or 
non-dihydropiridine) is effective and safe for renoprotection 
in diabetes patients (hypertensive or normotensive), and 
useful when a greater antiproteinuric effect is needed. The 
fixed dose combination of an ACE inhibitor with verapamil 
is able to avoid the evolution from normoalbuminury 
to microalbuminury. But the protective role of these 
combinations in non-diabetes nephropathies is unclear.
Fixed-dose combination advantages 
(Table 3)
The BP control rate in the United States is 27% to 29%,48 
and that in Mexico is about 19%. Therefore, about 70% of 
patients will need combinations of antihypertensive drugs to 
reach the recommended goals.3
Poor compliance to medication contributes to these low 
control rates. Complexity of treatment, and polypharmacy, 
and the number of doses to be taken during the day are 
determinants of poor compliance.49
A combination of agents from different drug classes is 
2 to 5 times more effective in lowering BP than increasing 
the dose of monotherapy.4,5 In addition, doubling the dose of 
monotherapy reduces coronary events by 29% and cerebro-
vascular events by 40%, whereas combining 2 drugs with a 
different mechanism of action would reduce coronary events 
by 40%, and stroke by 54%.5
A low dose of 2 agents reduces adverse events, too, not 
only those that are dose-related, but also because the mecha-
nism of action of one drug may interfere with the pathways for 
adverse effects of the second drug, ie, diuretics avoid the water 
retention induced by vasodilators, RAAS inhibitors avoid the 
RAAS activation produced by diuretics and CCB.47
Fixed-dose combinations may simplify the treatment regi-
men, and favor patient compliance; in fact, the risk of non-
compliance to therapy in hypertensive patients is reduced by 
24% (P  0.0001) by fixed-dose combinations compared with 
free drug combination regimens.49 A fixed-dose combination 
may also cost less than the individual components.9,47
The fixed-dose combination of a RAAS inhibitor with 
a CCB is an effective and safe option for the treatment 
of hypertensive patients who do not reach their BP goals. 
This combination facilitates compliance, and has a lower 
incidence of side effects and at a lower cost. However it has 
Table 3 Advantages of fixed-dose combination of antihypertensive 
agents
Simplification of treatment
Reduction of costs
Improvement of compliance
Those described in Table 1Integrated Blood Pressure Control 2009:2 61
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the inconvenience of being less flexible when dose needs to 
be adjusted, since usually there are only 1 or 2 presentations 
of each preparation.
Conclusion
Although hypertension is a major risk factor for cardiac and 
cerebrovascular events, and BP control reduces the risk of 
stroke and cardiovascular events, the actual control rate is 
unacceptably low, making combination therapy necessary 
to achieve therapeutic goals. A combination of agents from 
different classes is 2 to 5 times more effective in lowering 
BP than increasing the dose of monotherapy.
There are many drug choices for combination therapy. 
Combination therapy of CCB plus inhibitors of RAAS are 
efficacious and safe, and have been considered rational by 
both the JNC 7 and the ESHCG.
The combination of an inhibitor of the RAAS with a CCB 
(dihydropiridine or non-dihydropiridine) includes drugs with 
differing mechanism of action, and is effective and safe for 
the management of hypertensive patients because it produces 
additive BP lowering while minimizing side effects. The 
combination of agents from these 2 families has been shown 
to produce target organ protection. Several studies such as 
ACCOMPLISH and ASCOTBPLA have shown that this 
combination reduces cardiovascular morbidity and mortality, 
and new-onset diabetes.
The combination has also been shown to have a 
renoprotective action superior to monotherapy, and beneficial 
metabolic effects, which led the ESHCG to recommend this 
association in patients at high risk for developing diabetes, 
who require combination therapy to reach the therapeutic 
goals.
Fixed-dose combination increases compliance, simplifies 
treatment and reduces cost, and must be borne in mind when 
planning antihypertensive treatment in patients uncontrolled 
with monotherapy.
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